The Global Influenza Diagnostic Market is expected to grow from USD 841.62 Million in 2019 to USD 1,397.88 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 8.82%.

Market Segmentation & Coverage:

This research report categorizes the Influenza Diagnostic to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Test Type, the Influenza Diagnostic Market studied across Cell Culture, Rapid Influenza Diagnostic Tests, and Reverse Transcription-Polymerase Chain Reaction (RT-PCR).

Based on End User, the Influenza Diagnostic Market studied across Hospitals, Laboratories, and Point-of-Care Testing.

Based on Geography, the Influenza Diagnostic Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Influenza Diagnostic Market including Abbott Laboratories, Alere Inc., BD Medical, DiaSorin, Luminex Corporation, Quidel Corporation, Roche Diagnostics, SA Scientific, Sekisui Diagnostics, and Thermo Fisher Scientific.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Influenza Diagnostic Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Influenza Diagnostic Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Influenza Diagnostic Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Influenza Diagnostic Market?

4. What is the competitive strategic window for opportunities in the Global Influenza Diagnostic Market?

5. What are the technology trends and regulatory frameworks in the Global Influenza Diagnostic Market?

6. What are the modes and strategic moves considered suitable for entering the Global Influenza Diagnostic Market?

1.1. Objectives of the Study

1.2. Market Segmentation & Coverage

1.3. Years Considered for the Study

1.4. Currency & Pricing

1.5. Language

1.6. Stakeholders

2.1. Research Process

2.1.1. Define: Research Objective

2.1.2. Determine: Research Design

2.1.3. Prepare: Research Instrument

2.1.4. Collect: Data Source

2.1.5. Analyze: Data Interpretation

2.1.6. Formulate: Data Verification

2.1.7. Publish: Research Report

2.1.8. Repeat: Report Update

2.2. Research Execution

2.2.1. Initiation: Research Process

2.2.2. Planning: Develop Research Plan

2.2.3. Execution: Conduct Research

2.2.4. Verification: Finding & Analysis

2.2.5. Publication: Research Report

2.3. Research Outcome

3.1. Market Outlook

3.2. Test Type Outlook

3.3. End User Outlook

3.4. Geography Outlook

3.5. Competitor Outlook

4.1. Introduction

5.1. Introduction

5.2. Drivers

5.3. Restraints

5.4. Opportunities

5.5. Challenges

6.1. Porters Five Forces Analysis

6.1.1. Threat of New Entrants

6.1.2. Threat of Substitutes

6.1.3. Bargaining Power of Customers

6.1.4. Bargaining Power of Suppliers

6.1.5. Industry Rivalry

6.2. Cumulative Impact of COVID-19

6.3. Client Customizations

7.1. Introduction

7.2. Cell Culture

7.3. Rapid Influenza Diagnostic Tests

7.4. Reverse Transcription-Polymerase Chain Reaction (RT-PCR)

8.1. Introduction

8.2. Hospitals

8.3. Laboratories

8.4. Point-of-Care Testing

9.1. Introduction

9.2. Americas

9.2.1. Argentina

9.2.2. Brazil

9.2.3. Canada

9.2.4. Mexico

9.2.5. United States

9.3. Asia-Pacific

9.3.1. Australia

9.3.2. China

9.3.3. India

9.3.4. Indonesia

9.3.5. Japan

9.3.6. Malaysia

9.3.7. Philippines

9.3.8. South Korea

9.3.9. Thailand

9.4. Europe, Middle East & Africa

9.4.1. France

9.4.2. Germany

9.4.3. Italy

9.4.4. Netherlands

9.4.5. Qatar

9.4.6. Russia

9.4.7. Saudi Arabia

9.4.8. South Africa

9.4.9. Spain

9.4.10. United Arab Emirates

9.4.11. United Kingdom

10.1. Introduction

10.2. 360iResearch Competitive Strategic Window, by Test Type

10.3. 360iResearch Competitive Strategic Window, by End User

10.4. 360iResearch Competitive Strategic Window, by Geography

11.1. 360iResearch FPNV Positioning Matrix

11.1.1. Quadrants

11.1.2. Business Strategy

11.1.3. Product Satisfaction

11.2. 360iResearch Market Ranking Analysis

11.3. 360iResearch Market Share Analysis

11.4. 360iResearch Competitive Scenario

11.4.1. Merger & Acquisition

11.4.2. Agreement, Collaboration, & Partnership

11.4.3. New Product Launch & Enhancement

11.4.4. Investment & Funding

11.4.5. Award, Recognition, & Expansion

12.1. Abbott Laboratories

12.2. Alere Inc.

12.3. BD Medical

12.4. DiaSorin

12.5. Luminex Corporation

12.6. Quidel Corporation

12.7. Roche Diagnostics

12.8. SA Scientific

12.9. Sekisui Diagnostics

12.10. Thermo Fisher Scientific

13.1. Discussion Guide

13.2. Edition Details

13.3. License Details

13.4. Pricing Details

TABLE 1. GLOBAL INFLUENZA DIAGNOSTIC MARKET SIZE, 2017-2025 (USD MILLION)

TABLE 2. GLOBAL INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 3. GLOBAL INFLUENZA DIAGNOSTIC MARKET SIZE, BY CELL CULTURE, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 4. GLOBAL INFLUENZA DIAGNOSTIC MARKET SIZE, BY RAPID INFLUENZA DIAGNOSTIC TESTS, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 5. GLOBAL INFLUENZA DIAGNOSTIC MARKET SIZE, BY REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION (RT-PCR), BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 6. GLOBAL INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 7. GLOBAL INFLUENZA DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 8. GLOBAL INFLUENZA DIAGNOSTIC MARKET SIZE, BY LABORATORIES, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 9. GLOBAL INFLUENZA DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 10. GLOBAL INFLUENZA DIAGNOSTIC MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 11. AMERICAS INFLUENZA DIAGNOSTIC MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 12. AMERICAS INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 13. AMERICAS INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 14. ARGENTINA INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 15. ARGENTINA INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 16. BRAZIL INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 17. BRAZIL INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 18. CANADA INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 19. CANADA INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 20. MEXICO INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 21. MEXICO INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 22. UNITED STATES INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 23. UNITED STATES INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 24. ASIA-PACIFIC INFLUENZA DIAGNOSTIC MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 25. ASIA-PACIFIC INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 26. ASIA-PACIFIC INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 27. AUSTRALIA INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 28. AUSTRALIA INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 29. CHINA INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 30. CHINA INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 31. INDIA INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 32. INDIA INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 33. INDONESIA INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 34. INDONESIA INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 35. JAPAN INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 36. JAPAN INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 37. MALAYSIA INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 38. MALAYSIA INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 39. PHILIPPINES INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 40. PHILIPPINES INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 41. SOUTH KOREA INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 42. SOUTH KOREA INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 43. THAILAND INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 44. THAILAND INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 45. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTIC MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 46. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 47. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 48. FRANCE INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 49. FRANCE INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 50. GERMANY INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 51. GERMANY INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 52. ITALY INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 53. ITALY INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 54. NETHERLANDS INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 55. NETHERLANDS INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 56. QATAR INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 57. QATAR INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 58. RUSSIA INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 59. RUSSIA INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 60. SAUDI ARABIA INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 61. SAUDI ARABIA INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 62. SOUTH AFRICA INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 63. SOUTH AFRICA INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 64. SPAIN INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 65. SPAIN INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 66. UNITED ARAB EMIRATES INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 67. UNITED ARAB EMIRATES INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 68. UNITED KINGDOM INFLUENZA DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2025 (USD MILLION)

TABLE 69. UNITED KINGDOM INFLUENZA DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 70. GLOBAL INFLUENZA DIAGNOSTIC MARKET: SCORES

TABLE 71. GLOBAL INFLUENZA DIAGNOSTIC MARKET: BUSINESS STRATEGY

TABLE 72. GLOBAL INFLUENZA DIAGNOSTIC MARKET: PRODUCT SATISFACTION

TABLE 73. GLOBAL INFLUENZA DIAGNOSTIC MARKET: RANKING

TABLE 74. GLOBAL INFLUENZA DIAGNOSTIC MARKET: MERGER & ACQUISITION

TABLE 75. GLOBAL INFLUENZA DIAGNOSTIC MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP

TABLE 76. GLOBAL INFLUENZA DIAGNOSTIC MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT

TABLE 77. GLOBAL INFLUENZA DIAGNOSTIC MARKET: INVESTMENT & FUNDING

TABLE 78. GLOBAL INFLUENZA DIAGNOSTIC MARKET: AWARD, RECOGNITION, & EXPANSION

TABLE 79. GLOBAL INFLUENZA DIAGNOSTIC MARKET: EDITION DETAILS

TABLE 80. GLOBAL INFLUENZA DIAGNOSTIC MARKET: LICENSE DETAILS

TABLE 81. GLOBAL INFLUENZA DIAGNOSTIC MARKET: PRICING DETAILS